Evidence map›Paper›PMID 35819062›Full record

ArticleACS chemical biology2022

Applying Promiscuous RiPP Enzymes to Peptide Backbone

Snigdha Sarkar, Wenjia Gu, Eric W Schmidt

Abstract read
In one paragraph

Article in ACS chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Myxarylin: TotalJournal of the American Chemical Society · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Genome Mining and Biological Engineering of Type III Borosins from Bacteria.International journal of molecular sciences · 2024
    Article
  8. Use of a head-to-tail peptide cyclase to prepare hybrid RiPPs.Chemical communications (Cambridge, England) · 2024
    Article
  9. Article
  10. Article
  11. Promiscuous Enzymes for Residue-Specific Peptide and Protein Late-Stage Functionalization.Chembiochem : a European journal of chemical biology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Snigdha SarkarDepartment of Medicinal Chemistry, University of Utah, Salt Lake City, Utah 84112, United States.
Wenjia GuDepartment of Medicinal Chemistry, University of Utah, Salt Lake City, Utah 84112, United States.
Eric W SchmidtDepartment of Medicinal Chemistry, University of Utah, Salt Lake City, Utah 84112, United States.ORCID 0000-0001-5839-694X

Funding

Symbiosis and Chemical Diversity GenerationR35GM122521 · NIGMS · UNIVERSITY OF UTAH · PI SCHMIDT, ERIC W · 2017 to 2021
$2.9M
NIGMS NIH HHS R35 GM122521
6 · The paper itself

Abstract

The methylation of peptide backbone amides is a hallmark of bioactive natural products, and it also greatly modifies the pharmacology of synthetic peptides. Usually, bioactive

Indexed as

PeptidesPeptides, CyclicBiosynthetic PathwaysMethylationPeptide HydrolasesProtein Processing, Post-TranslationalPeptide HydrolasesPeptidesPeptides, Cyclic

Identifiers

PMID35819062
PMCPMC9526446

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.